Tumorbiology and targeted treatment workshop

Molecular Tumor Biology and Targeted Treatment in Gynaecological Malignancies Workshop

April 7-8, 2017, Leuven, Belgium

 

Confirmations will be made on a first-come-first-served basis
Application process open

Background

This 2-day residential workshop will cover the molecular background of the common gynecological cancers, pathways involved in their carcinogenesis, potential targets for individualized treatment but also genetics and evolving therapeutics and their toxicity. Targeted treatments are already used in the clinic and expected to grow since most pharmaceutical companies have several targeted drugs in their pipeline, highlighting the need of good knowledge in clinical practice. Contents will be delivered by clinically oriented, multidisciplinary, plenary lectures.

This workshop also covers 3 parallel practical sessions on tumor immunology, and also interactive case presentations and group discussions.

Main topics: lueven1
•    Cancer genetics
•    Molecular pathways in ovarian cancer
•    Molecular pathways in low-grade ovarian cancer
•    Molecular pathways in endometrial cancer
•    Molecular pathways in cervical cancer
•    Targeting angiogenesis
•    Targeting tyrosinkinases
•    Targeting PARP
•    Immunotherapy in gynecological malignancies
•    Toxicities of immunotherapy and their management
•    Why do studies of targeted treatment fail?

 

Learning Objectives

The aim of this 2-days workshop is to enhance the attendees´ ability to understand the molecular pathways of gynaecological malignancies. Attendees will also learn about the genetic disposition, potential role of cancer genetics in treatment decisions and counselling of patients. The workshop will review the mechanisms and current evidence of targeted treatment strategies and will help participants to recognise side effects and manage toxicities appropriately.

The workshop will be as interactive as possible allowing sufficient time for group discussions, also including a session where attendees are invited to present case scenarios from their clinical practice.

 

Application Process
Registration Fee & Travel
Application Process

Workshop attendance is limited to 40 participants.

Only applicants who are active ESGO/ENGYO members and who have paid the course fee will be considered for participation.

Paid ESGO/ENYGO membership for 2017 is a mandatory condition for being considered.

Not yet a member?

Renew or join ESGO/ENYGO today!

Application deadline:   March 3, 2017

Download the application form

Please note that a short CV is mandatory parts of the application.

Email the completed and signed application form with your CV to: enygo.secretariat@esgomail.org

Only applications sent by email will be considered.

Confirmations will be made on a first-come-first-served basis.

Registration Fee & Travel

Registration Fee: 150 € or 250 € incl. VAT

The fee includes:

•    Admission to the workshop
•    2 nights accommodation in either two  beds room shared with other participant (150 €) or single room (250 €), breakfast included
•    Coffee breaks and lunch
•    Dinner on Friday, April 7, 2017

 

Participants are expected to cover their own travel costs.

Payment details and cancellation conditions:

The course fee must be paid upon confirmation of attendance. The payment can be processed only by bank transfer; bank details will be available in the confirmation letter. The reservation can only be confirmed upon receipt of payment. In case of cancellation, the fee will be refunded, provided a written request is received by March 17, 2017. No refund can be made if the notice of cancellation is received after this date or in the case of a no-show.

Contact

For any queries please contact:  enygo.secretariat@esgomail.org

 

ENYGO_Titles_Leuven
Under the auspices of

KU Leuven and University Hospitals, Leuven, Belgium

leuven-logos-2x

Workshop Programme

Download the workshop Scientific programme

Organising team & Faculty

  • Kristina Lindemann, ENYGO EEG member, Oslo University Hospital, Norway
  • David Lindquist, ENYGO EEG member, Umeå University, Sweden
  • Sileny Han, ENYGO NatRep, UZ Leuven, Belgium
  • Ignace B. Vergote, UZ Leuven, Belgium
  • Jonathan Ledermann, ESGO Council member, UCL Cancer Institute, London, UK
  • Eva Lundin, Medical Biosciences, Umeå University, Sweden
  • Oliver Bechter, UZ Leuven, Belgium
  • An Coosemans, UZ Leuven, Belgium
  • Henrica Werner, Haukeland University Hospital, Norway
  • Miriam Mints, Karolinska Institute, Stockholm, Sweden
  • Heidi Lyng, Oslo University Hospital, Norway
  • Sevilay Altintas, University Hospital Antwerp, Belgium

Workshop Venue

University Hospital, Leuven, Belgium